Therapeutic effects of roxithromycin and azithromycin in experimental murine brucellosis.

Abstract

Mice infected with Brucella melitensis were treated with azithromycin or roxithromycin at a dose of 50 mg/kg/day i.p. alone and in combination with streptomycin 75 mg/kg/day for 14 days. Streptomycin at this dose was previously documented to be ineffective against murine brucellosis. Azithromycin- and azithromycin/streptomycin-treated animals demonstrated a significantly better cure rate than controls. Therapy failure was observed in all mice treated with roxithromycin 50 mg/kg/day i.p. alone or in combination with streptomycin 75 mg/kg/day. Our findings demonstrate that azithromycin cures experimental murine brucellosis and may be an effective alternative in the therapy of human brucellosis.

• Authors: R Lang, B Shasha, N Ifrach, S Tinman, E Rubinstein
• Journal: Chemotherapy (Chemotherapy) 1994 Jul-Aug Vol. 40 Issue 4 Pg. 252-5 ISSN: 0009-3157 [Print] Switzerland
• PMID: 8082413 (Publication Type: Comparative Study, Journal Article)

Chemical References

• Roxithromycin
• Azithromycin

Topics

• Animals
• Azithromycin (pharmacokinetics, therapeutic use)
• Brucella melitensis (growth & development)
• Brucellosis (drug therapy, microbiology)
• Colony Count, Microbial
• Mice
• Microbial Sensitivity Tests
• Roxithromycin (pharmacokinetics, therapeutic use)